Cabotegravir/rilpivirine (Cabenuva) vs Doravirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Cabotegravir/rilpivirine (Cabenuva)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Weak signal

NCT05917509 · Phase 3 · completed

The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT06411223 (registry estimate)

Reported efficacy

Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)

Result source: NCT03299049

Doravirine · Pifeltro

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT02275780 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)

Result source: NCT02403674

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCabotegravir/​rilpivirine (Cabenuva)Doravirine
HIV-1 RNA below 50 copies/mL (week 48)94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT036393110% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778
CD4 count, change (week 48)270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345

HIV-1 RNA below 50 copies/mL (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
Doravirine
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674

HIV-1 RNA 50 copies/mL or more (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311
Doravirine
0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778

CD4 count, change (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
Doravirine
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Cabotegravir/rilpivirine (Cabenuva): 10 of 10 rows · Doravirine: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCabotegravir/​rilpivirine (Cabenuva)
Rows use multiple source trials
Doravirine
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
276 cells/uL @ 324wk30 mga,b,c,d,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
272 cells/uL @ 324wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
402 cells/uL @ 324wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
42.5 cells/uL @ 96wkb,c,d,e
NCT03332095 · Phase 1/2 · combination
HIV-1 RNA
absolute change · log
Induction
-1.577 vs -0.168 placebo log @ 1wk5 mgf,c,g
NCT00920426 · Phase 2 · registry result, not featured evidence
-1.23 vs 0.03 placebo log @ 1wka,f,c,g
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
-1.23 vs -0.44 ISL log @ 1wk
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-2.215 log @ 324wk30 mga,b,c,d,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
-2.438 log @ 324wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-2.488 log @ 324wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-4.3 log @ 96wkb,c,d,e
NCT03332095 · Phase 1/2 · combination
HIV-1 RNA Ge50 Copies
responder rate · % of participants
No placebo or comparator arm
2.2% (n=93) @ 12wk400 mg + 600 mg Q4Wh,c,g,i
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
2.9% (n=34) @ 24wkh,c,g,i
NCT04295772 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
87% (n=430) @ 52wkj,c,g,k
NCT04399551 · Phase 3 · registry result, not featured evidence
92.5% (n=40) @ 96wkj,c,g,k
NCT03332095 · Phase 1/2 · combination
Virologic Failure
event count · % of participants
Maintenance
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q4Wa,l,m
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more dose
1.7% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
0% (n=47) vs 0% (n=49) INSTI+TAF/FTC @ 48wk*100 mga,l,m
NCT04636437 · Phase 4 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more dose
0% (n=49) vs 0% (n=49) INSTI+TAF/FTC @ 48wk*100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
Dropout rate
13.6%n
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
8.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
13.1%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
6.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
11.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
1.3%CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
15.6%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
11.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
13.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
15.2%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
24.2%100 mgo
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
19.6%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
10%Cohort 1: DOR
NCT03332095 · Phase 1/2
2.2%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
20.4%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
8.2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
0%
NCT04689737 · Phase 4 · registry result, not featured evidence
30.4%DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
80.2%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
17%Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
42.9%DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
33.3%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
43.6%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
28.6%
NCT04900974 · Phase 1 · registry result, not featured evidence
0%
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—n
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
5.7%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
3.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
4.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
1.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
1.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
4.9%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
1.6%100 mgo
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
3%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
—Cohort 1: DOR
NCT03332095 · Phase 1/2
—Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
—200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
Serious AEs
0%n
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
3.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
6.3%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
3.4%Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
4%
NCT04399551 · Phase 3 · registry result, not featured evidence
7.8%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
12.7%Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
10%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
26.5%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
11.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
0%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.4%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
17%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.1%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.6%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
15.2%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
12.5%Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
7.1%300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
11.7%100 mgo
NCT02275780 · Phase 3 · combination
show 44 more results
6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
6%DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
4.5%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
5.2%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
6.3%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
8.2%DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
—MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
0%Cohort 1: DOR
NCT03332095 · Phase 1/2
4.4%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
10.6%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
25%
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
4.3%DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
6.2%DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.6%DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.5%DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
6.4%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
5.3%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.1%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
0%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.7%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.8%Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
4%Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
3.7%Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
2.7%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
10.2%100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
7.3%200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
2.3%50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
10%25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
0%
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
n
injection site discomfort 13.6%
injection site pain 13.6%
fatigue 2.3%
NCT04982445 · Phase 4 · registry result, not featured evidence
show 40 more results
400 mg + 600 mg Q4W
injection site pain 32.3%
injection site nodule 9.7%
injection site induration 2.2%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 74.2%
injection site nodule 64.5%
injection site erythema 51.6%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 30.9%
injection site nodule 3.2%
injection site pruritus 2.1%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
injection site pain 65.2%
covid-19 17.9%
headache 12.5%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 60.6%
covid-19 19.4%
injection site induration 11.4%
NCT04542070 · Phase 3 · registry result, not featured evidence
Q2M
injection site pain 37.9%
covid-19 14.5%
arthralgia 0%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 80.2%
covid-19 18.4%
injection site induration 11.2%
NCT04399551 · Phase 3 · registry result, not featured evidence
injection site pain 55.7%
injection site discomfort 26.1%
fatigue 20%
NCT04001803 · Phase 3 · registry result, not featured evidence
creatinine renal clearance decreased 19.7%
lipase increased 11.3%
chills 7%
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 99.1%
injection site nodule 49.6%
nasopharyngitis 47%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 80%
injection site nodule 50%
nasopharyngitis 50%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 96.5%
nasopharyngitis 47%
injection site nodule 40%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 91.2%
injection site nodule 35.3%
covid-19 26.5%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
Q2M
injection site pain 74.4%
covid-19 33.3%
upper respiratory tract infection 17.8%
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
30 mg
headache 21.7%
nausea 18.3%
upper respiratory tract infection 13.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 26.4%
diarrhoea 13.2%
rash 11.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 31.9%
back pain 12.8%
oropharyngeal pain 12.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
headache 21.3%
diarrhoea 18%
nausea 18%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 21.8%
nausea 14.5%
bronchitis 10.9%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 27.5%
anxiety 11.8%
sinusitis 11.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
nausea 23.3%
headache 21.7%
diarrhoea 16.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
upper respiratory tract infection 17.3%
depression 9.6%
diarrhoea 9.6%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
diarrhoea 13%
nasopharyngitis 10.9%
gonorrhoea 8.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
dizziness 37.5% (placebo 0%)
dyspepsia 25% (placebo 0%)
headache 25% (placebo 0%)
NCT00920426 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain 0% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood bilirubin increased 0% (placebo 50%)
NCT00920426 · Phase 2 · registry result, not featured evidence
30 mg
atrioventricular block first degree 7.7%
decreased appetite 7.7%
headache 7.7%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
aspartate aminotransferase increased 50%
blood creatine phosphokinase increased 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site nodule 55.6%
injection site erythema 44.4%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site haemorrhage 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 72.7%
injection site pain 72.7%
injection site induration 45.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site induration 100%
injection site pain 100%
injection site bruising 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 75%
headache 37.5%
injection site swelling 37.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
catheter site bruise 50%
injection site erythema 50%
injection site induration 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 94.4%
headache 77.8%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 100%
injection site pruritus 87.5%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
injection site erythema 100%
injection site pain 100%
injection site warmth 88.9%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
accident 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site swelling 70%
headache 60%
NCT04484337 · Phase 1 · registry result, not featured evidence
30 mg
blood creatine phosphokinase increased 6.7%
contusion 6.7%
body temperature increased 0%
NCT03149848 · Phase 1 · registry result, not featured evidence
300 mg + 30 mg
body temperature increased 7.1%
headache 7.1%
hyperkeratosis 7.1%
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
100 mgo
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · combination
show 33 more results
nasopharyngitis 13.7%
upper respiratory tract infection 7.2%
headache 6.2%
NCT02403674 · Phase 3 · HIV · phase 3
headache 15.9%
diarrhoea 13.7%
nasopharyngitis 13.7%
NCT02403674 · Phase 3 · HIV · phase 3
nasopharyngitis 9.7%
upper respiratory tract infection 7.1%
diarrhoea 6.3%
NCT02403674 · Phase 3 · HIV · phase 3
dizziness 38.2%
diarrhoea 15.9%
headache 15.4%
NCT02403674 · Phase 3 · HIV · phase 3
aspartate aminotransferase increased 22.2%
blood alkaline phosphatase increased 11.1%
blood glucose increased 11.1%
NCT03332095 · Phase 1/2
glomerular filtration rate decreased 55.6%
alanine aminotransferase increased 46.7%
blood creatinine increased 46.7%
NCT03332095 · Phase 1/2 · combination
100 mg
creatinine renal clearance decreased 10.6%
low density lipoprotein increased 6.4%
abdominal pain upper 2.1%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
100 mg
creatinine renal clearance decreased 8.2%
aspartate aminotransferase increased 4.1%
alanine aminotransferase increased 2%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
vomiting 25%
headache 12.5%
NCT04689737 · Phase 4 · registry result, not featured evidence
headache 8.1%
covid-19 5.9%
arthralgia 5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 13.1%
lymphocyte count decreased 10.5%
cd4 lymphocytes decreased 9.2%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 32.3%
cd4 lymphocytes decreased 23.7%
covid-19 12.4%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 15.9%
cd4 lymphocytes decreased 11.4%
covid-19 1.5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 2.6%
nasopharyngitis 2%
diarrhoea 1%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
100 mg/0.75 mg
covid-19 14.1%
headache 10.4%
lymphocyte count decreased 9.1%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 24.1%
cd4 lymphocytes decreased 10.5%
covid-19 7.5%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 17.1%
cd4 lymphocytes decreased 8.2%
upper respiratory tract infection 2.7%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 14.3%
accidental overdose 0%
arthralgia 0%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
upper respiratory tract infection 6.3%
insomnia 1.8%
headache 0.9%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
headache 10.7%
accidental overdose 7.1%
covid-19 5.4%
NCT04223778 · Phase 3 · registry result, not featured evidence
lymphocyte count decreased 20.2%
cd4 lymphocytes decreased 14%
covid-19 13%
NCT04223778 · Phase 3 · registry result, not featured evidence
covid-19 17.5%
lymphocyte count decreased 13.5%
cd4 lymphocytes decreased 12%
NCT04223778 · Phase 3 · registry result, not featured evidence
blood creatine phosphokinase increased 28.6% (placebo 14.3%)
diarrhoea 28.6% (placebo 14.3%)
anaemia 14.3% (placebo 0%)
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
dizziness 33.3%
dyspepsia 33.3%
headache 33.3%
NCT04295772 · Phase 2 · registry result, not featured evidence
covid-19 100%
adjustment disorder 0%
back pain 0%
NCT04295772 · Phase 2 · registry result, not featured evidence
oropharyngeal pain 10.8%
cough 8.1%
nasal congestion 8.1%
NCT04295772 · Phase 2 · registry result, not featured evidence
cough 28.6%
oropharyngeal pain 21.4%
rhinorrhoea 21.4%
NCT04295772 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 17.6%
diarrhea 14.8%
dizziness 14.8%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 29.3%
nausea 22%
headache 17.1%
NCT01632345 · Phase 2 · registry result, not featured evidence
50 mg
abnormal dreams 20.9%
nausea 16.3%
headache 14%
NCT01632345 · Phase 2 · registry result, not featured evidence
25 mg
diarrhea 25%
fatigue 17.5%
influenza 15%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 33.3%)
abdominal pain 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
25 mg
alanine aminotransferase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 0%)
decreased appetite 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 1/2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context differs: pooled versus combination.
  5. eAssessment timepoints differ: 324 weeks versus 96 weeks.
  6. fTrial phases differ: Phase 2 versus Phase 3.
  7. gTreatment context has not been resolved for both arms.
  8. hTrial phases differ: Phase 3 versus Phase 2.
  9. iAssessment timepoints differ: 12 weeks versus 24 weeks.
  10. jTrial phases differ: Phase 3 versus Phase 1/2.
  11. kAssessment timepoints differ: 52 weeks versus 96 weeks.
  12. lTrial phases differ: Phase 2 versus Phase 4.
  13. mPopulation context differs: registered conditions differ.
  14. nPopulation comparability has not been reviewed for these studies.
  15. oPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cabotegravir/rilpivirine (Cabenuva)

HIV-1 RNA Less Than 50 Copies Per 100% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
99% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
90% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure 0% (n=93)400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0% (n=115)
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0% (n=430) @ 4.33wk
event count · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 6 more results
0% (n=430) @ 8.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 17.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 26wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 34.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0.2% (n=430) @ 43.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=430) @ 52wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
HIV-1 RNA LT 50 Copies 93.9% (n=115) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04001803 · Phase 3 · registry result, not featured evidence
show 25 more results
94.8% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
91.3% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
90.4% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
87.8% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
96% (n=115) @ 4.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
98% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 56.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 65wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 69.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 78wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 82.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 91wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 95.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 104wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 108.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 117wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 121.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 130wk
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0.07 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.04 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Treatment Failure 0.14 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 Cumulative probability @ 44wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 0.13 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.12 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 9.9% (n=71) @ 44wk
event count · % of participants
No placebo or comparator arm
HIV-1 RNA ≥ 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
Virologic Response 50 Copies Snapshot 81.7% (n=71) @ 44wk
responder rate · % of participants
No placebo or comparator arm
HIV-1 RNA < 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
HIV-1 RNA Less Than 50 Copies 99% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
95% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q8W
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 98% (n=115) vs 93% (n=56) CAB 30 mg+ABC/3TC @ 4wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Week 4
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
97% (n=115) vs 93% (n=56) CAB 30 mg+ABC/3TC @ 4wkIM-Q8W
HIV-1 RNA<50 c/mL, Week 4
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 97% (n=115) vs 95% (n=56) CAB 30 mg+ABC/3TC @ 8wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Week 8
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
98% (n=115) vs 95% (n=56) CAB 30 mg+ABC/3TC @ 8wkIM-Q8W
HIV-1 RNA<50 c/mL, Week 8
NCT02120352 · Phase 2 · registry result, not featured evidence · combination

+ 163 further endpoints in the CSV export.

Doravirine

LDL-C -4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Maintenance
Change from Baseline
NCT02275780 · Phase 3 · combination
Non-HDL-C Change mg/dL -5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Maintenance
Change from Baseline
NCT02275780 · Phase 3 · combination
HDL-C Change mg/dL 3.94 vs 4.15 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Maintenance
Change from Baseline
NCT02275780 · Phase 3 · combination
Total Cholesterol Change mg/dL -1.37 mg/dL @ 48wk100 mg
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02275780 · Phase 3 · combination
Triglyceride Change mg/dL -3.14 vs 21.97 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Maintenance
Change from Baseline
NCT02275780 · Phase 3 · combination
HIV-1 RNA Less Than 40 Copies 83.3% (n=383) vs 79.1% (n=383) Daurunavir + Ritonavir @ 48wk100 mg
responder rate · % of participants
Maintenance
NCT02275780 · Phase 3 · combination
show 3 more results
72% (n=379) vs 64.4% (n=376) Daurunavir + Ritonavir @ 96wk100 mg
NCT02275780 · Phase 3 · combination
83.8% (n=364) vs 79.7% (n=364) ATRIPLA @ 48wk
NCT02403674 · Phase 3 · HIV · phase 3
76.1% (n=364) vs 72.8% (n=364) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
CD4+ 198.4% (n=344) vs 188.4% (n=329) ATRIPLA @ 48wk
absolute change · percentage points
Maintenance
NCT02403674 · Phase 3 · HIV · phase 3
show 3 more results
237.7% (n=337) vs 223% (n=311) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
-0.7% (n=313) vs 8.7% (n=311) Baseline Antiretroviral Therapy (ART) @ 48wk
NCT04223778 · Phase 3 · registry result, not featured evidence
5.29% (n=289) vs 0.16% (n=285) Baseline Antiretroviral Therapy (ART) @ 96wk
NCT04223778 · Phase 3 · registry result, not featured evidence
LDL-C -1.58% (n=330) vs 8.74% (n=305) ATRIPLA @ 48wk
percent change · % of baseline
Maintenance
NCT02403674 · Phase 3 · HIV · phase 3
Non-HDL-C -3.83% (n=333) vs 13.26% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
Maintenance
NCT02403674 · Phase 3 · HIV · phase 3
Total Cholesterol -1.97% (n=333) vs 21.77% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
Maintenance
NCT02403674 · Phase 3 · HIV · phase 3
Triglycerides -12.4% (n=333) vs 22.01% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
Maintenance
NCT02403674 · Phase 3 · HIV · phase 3
HDL-C 1.86% (n=333) vs 8.51% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
Maintenance
NCT02403674 · Phase 3 · HIV · phase 3

+ 35 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Doravirine's landscape